Yazılar

Bristol Myers Partners With Microsoft for AI-Driven Lung Cancer Detection

/in /tarafından

Bristol Myers Squibb has signed a partnership with Microsoft to use artificial intelligence-powered radiology tools to speed up the early detection of lung cancer, the companies said on Tuesday.

Under the agreement, Bristol Myers will deploy U.S. Food and Drug Administration-cleared radiology AI algorithms through Microsoft’s Precision Imaging Network. The platform analyzes X-ray and CT scan images to help clinicians identify lung disease and is already used by hospitals across the United States.

The companies said the AI tools could help doctors detect hard-to-spot lung nodules and identify patients at earlier stages of disease, when treatment options are more effective. A key objective of the collaboration is to expand access to early lung cancer detection in medically underserved areas, including rural hospitals and community clinics.

Alexandra Goncalves, vice president and head of digital health at Bristol Myers Squibb, said the partnership combines Microsoft’s scalable imaging technology with Bristol Myers’ oncology expertise to create an AI-enabled workflow that supports faster and more accurate diagnosis of non-small cell lung cancer and guides patients toward appropriate care pathways.

Pharmaceutical companies are increasingly adopting AI to improve efficiency across research, development, and clinical workflows. The collaboration reflects a broader industry push to apply AI not only to drug discovery but also to diagnostics and patient care, particularly in oncology.

Bristol Myers, Takeda Join Forces on AI-Powered Drug Discovery Consortium

/in /tarafından

Bristol Myers Squibb, Takeda Pharmaceuticals, and Astex Pharmaceuticals announced a strategic collaboration to share proprietary molecular data for training an artificial intelligence model aimed at accelerating drug discovery and development.

The partnership joins a wider consortium that already includes major pharmaceutical players such as AbbVie and Johnson & Johnson, according to an announcement from Apheris, the German life sciences computing company facilitating the project.

FEDERATED AI FOR DRUG DEVELOPMENT

The companies will contribute data from several thousand experimentally determined protein–small molecule structures to train OpenFold3, an advanced AI model designed to predict protein-ligand interactions — a critical component in developing new medicines.

Unlike traditional data-sharing methods, this collaboration uses Apheris’ federated data platform, which allows multiple organizations to collaborate securely without exposing or transferring sensitive data. Each company’s dataset remains stored in its original location while being used to improve the AI model collectively.

“The federated approach allows us to advance predictive models for small molecule discovery in ways no single organization could achieve alone,” said Payal Sheth, Vice President of Discovery Biotherapeutics and Lead Discovery & Optimization at Bristol Myers Squibb.

A COLLABORATIVE AI STRUCTURAL BIOLOGY INITIATIVE

OpenFold3 serves as the flagship project of the AI Structural Biology Network, an industry-led consortium developed in collaboration with the AlQuraishi Lab at Columbia University. The initiative aims to push the boundaries of AI-driven molecular modeling and create a shared foundation for faster, more efficient therapeutic development.

Hans Bitter, Head of Computational Sciences at Takeda, said the collaboration fits seamlessly into the company’s broader digital strategy.
“This consortium really ties into our larger corporate goal of embedding AI throughout everything we do,” Bitter noted. “It’s a powerful example of how pharma companies can come together to achieve more for patients than we could individually.”

By combining their molecular and structural data through AI, the consortium partners hope to improve drug target identification, binding prediction accuracy, and development timelines, setting a new standard for AI-based biopharma collaboration.

Bristol Myers Squibb Beats Earnings Estimates and Raises Outlook Amid Cost-Cutting Measures

/in /tarafından

Bristol Myers Squibb reported strong second-quarter earnings, surpassing Wall Street expectations and raising its full-year guidance as part of its broader strategy to cut costs and reinvest in key drug brands and R&D programs. The pharmaceutical giant has outlined plans to reduce $1.5 billion in expenses by 2025, which includes laying off over 2,000 employees and consolidating its sites.

Key Financial Highlights:

  • Earnings per share: Adjusted EPS of $2.07, compared to an expected loss of $1.63.
  • Revenue: $12.2 billion, up 9% year-over-year, versus the expected $11.55 billion.
  • Net income: $1.68 billion, or 83 cents per share, down from $2.07 billion, or 99 cents per share, in the prior year.

Guidance Update:

  • Full-year revenue forecast: Now projected to increase at the “upper end” of the low single-digit range, up from a low single-digit increase.
  • Full-year adjusted earnings guidance: Raised to 60-90 cents per share, up from the previous forecast of 40-70 cents per share.

Shares of Bristol Myers rose nearly 8% following the earnings report.

Performance Drivers:

  • Eliquis: The blockbuster blood thinner recorded $3.42 billion in sales, a 7% increase year-over-year, aligning with analyst expectations. Eliquis, which Bristol Myers co-owns with Pfizer, is anticipated to lose market exclusivity by 2028.
  • Revlimid: Despite facing competition from generics, the blood cancer drug brought in $1.35 billion in sales, surpassing the estimated $1.09 billion.
  • Opdivo: The cancer drug generated $2.39 billion in sales, exceeding the expected $2.29 billion.

Growth Portfolio:

  • Reblozyl: Sales were above analysts’ expectations, contributing significantly to the company’s growth.
  • Opdualag and Camzyos: Both drugs, along with Opdivo, drove revenue growth within the portfolio.
  • Abecma: The cell therapy for multiple myeloma recorded $95 million in sales, close to the expected $95.8 million.

Bristol Myers continues to face pressure to innovate and introduce new drugs to compensate for revenue losses from key treatments like Revlimid, Eliquis, and Opdivo, which will eventually lose their market exclusivity.

The company’s proactive measures to cut costs and reinvest in strategic areas underscore its commitment to sustaining growth and competitiveness in the pharmaceutical industry.